Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands:comparative in vitro and in vivo studies by Persson, Morten et al.
Theranostics 2013, Vol. 3, Issue 9 
 
 
http://www.thno.org 
618 
Theranostics 
2013; 3(9):618-632. doi: 10.7150/thno.6810 
Research Paper 
Improved PET Imaging of uPAR Expression Using new 
64Cu-labeled Cross-Bridged Peptide Ligands: Compara-
tive in vitro and in vivo Studies 
Morten Persson1,2,3,4, Masood Hosseini1,5, Jacob Madsen4, Thomas J. D. Jørgensen6, Knud J Jensen1,5, An-
dreas Kjaer1,3,4, Michael Ploug1,2, 
1. The Danish-Chinese Center for Proteases and Cancer;  
2. Finsen Laboratory, Rigshospitalet & BRIC, Copenhagen Biocenter, Denmark;  
3. Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;  
4. Department of Clinical Physiology, Nuclear Medicine and PET, Center for Diagnostic Investigations, Rigshospitalet, Copenhagen, 
Denmark;  
5. Department of Chemistry, University of Copenhagen, Denmark;  
6. Department of Biochemistry and Molecular Biology, University of Southern Denmark, Denmark.  
 Corresponding author: Michael Ploug, PhD, Dr.Sci. Finsen Laboratory & BRIC, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200 – Copenhagen N, Denmark. 
E-mail: m-ploug@finsenlab.dk Tel: +45-35456037. 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2013.05.31; Accepted: 2013.07.21; Published: 2013.08.03 
Abstract 
The correlation between uPAR expression, cancer cell invasion and metastases is now well-established 
and has prompted the development of a number of uPAR PET imaging agents, which could potentially 
identify cancer patients with invasive and metastatic lesions. In the present study, we synthesized and 
characterized two new cross-bridged 64Cu-labeled peptide conjugates for PET imaging of uPAR and 
performed a head-to-head comparison with the corresponding and more conventionally used DOTA 
conjugate. Based on in-source laser-induced reduction of chelated Cu(II) to Cu(I), we now demonstrate 
the following ranking with respect to the chemical inertness of their complexed Cu ions: DOTA-AE105 
<< CB-TE2A-AE105 < CB-TE2A-PA-AE105, which is correlated to their corresponding demetallation 
rate. No penalty in the uPAR receptor binding affinity of the targeting peptide was encountered by 
conjugation to either of the macrobicyclic chelators (IC50 ~ 5-10 nM) and high yields and radiochemical 
purities (>95%) were achieved in all cases by incubation at 95°C. In vivo, they display identical tumor 
uptake after 1h, but differ significantly after 22 hrs, where the DOTA-AE105 uptake remains surprisingly 
high. Importantly, the more stable of the new uPAR PET tracers, 64Cu-CB-TE2A-PA-AE105, exhibits a 
significantly reduced liver uptake compared to 64Cu-DOTA-AE105 as well as 64Cu-CB-TE2A-AE105, 
(p<0.0001), emphasizing that our new in vitro stability measurements by mass spectrometry predicts in 
vivo stability in mice. Specificity of the best performing ligand, 64Cu-CB-TE2A-PA-AE105 was finally 
confirmed in vivo using a non-binding 64Cu-labeled peptide as control (64Cu-CB-TE2A-PA-AE105mut). 
This control PET-tracer revealed significantly reduced tumor uptake (p<0.0001), but identical hepatic 
uptake compared to its active counterpart (64Cu-CB-TE2A-PA-AE105) after 1h. In conclusion, our new 
approach using in-source laser-induced reduction of Cu(II)-chelated PET-ligands provides useful in-
formation, which are predictive for the tracer stability in vivo in mice. Furthermore, the increased sta-
bility of our new macrobicyclic 64Cu-CB-TE2A-PA-AE105 PET ligand is paralleled by an excellent im-
aging contrast during non-invasive PET scanning of uPAR expression in preclinical mouse cancer models. 
The translational promises displayed by this PET-tracer for future clinical cancer patient management 
remains, however, to be investigated.  
Key words: urokinase-type plasminogen activator receptor, CD87, positron emission tomography, 
biomarker, CB-TE2A, Ly-6, SPR, tumor targeting. 
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Introduction 
Development of novel PET ligands for cancer 
diagnosis and therapy monitoring has accelerated 
considerably during the last decade, reflecting the 
steadily growing knowledge on molecular drivers 
and biomarkers of pathogenesis in several human 
cancer diseases [1]. One receptor found to correlate to 
cancer pathogenesis due to its ability to modulate 
extracellular matrix degradation, which is considered 
to impact tumor invasion and metastasis, is the uro-
kinase-type plasminogen activator receptor (uPAR) 
[2, 3]. This high-affinity receptor for uPA is tethered to 
the cell surface via a glycosyl-phosphatidylinositol 
(GPI) membrane anchor [4]. Besides facilitating focal 
plasminogen activation by receptor-bound uroki-
nase-type plasminogen (uPA) [5], increasing evidence 
also implicates uPAR in cell adhesion and migration 
by modulating various cell signaling pathways [6]. 
Levels of shed forms of uPAR in blood furthermore 
predict poor prognosis in various cancer types such as 
breast, lung, prostate and colorectal cancer [7]. Since 
uPAR is implicated in the remodeling of the extra-
cellular matrix during cancer invasion, it is considered 
to be a relevant anti-cancer target [5, 8], and various 
cytotoxic intervention strategies targeting uPAR have 
accordingly been developed, including “intelligent” 
pro-drugs requiring proteolytic activation by recep-
tor-bound uPA [9], radiotherapeutics [10, 11], and 
uPAR-mediated internalization of functionalized na-
noparticles [12, 13, 14]. Another virtue from a thera-
peutic perspective is the assumption that uPAR is 
readily druggable due to its protein architecture with 
a large hydrophobic uPA-binding cavity [15], its ac-
cessibility on the cell surface, and the mild overt 
phenotypes associated with its genetic ablation [16, 
17]. Importantly, its expression levels in solid tumors 
are also considered an important biomarker for poor 
prognosis in various human cancers [7] rendering it 
an obvious candidate for non-invasive biomarker 
targeted PET imaging in the assessment of cancer pa-
tients with aggressive disease [5]. 
We have previously developed and character-
ized 64Cu- [18,19], 68Ga- [20], and 18F-labelled [21] 
peptide PET probes for non-invasive imaging of 
uPAR expressing in tumor bearing animals based on 
the macrocyclic chelators DOTA, NODAGA, and 
NOTA conjugated to a high-affinity 9-mer linear pep-
tide (denoted AE105), which specifically targets hu-
man uPAR [22] i.e. 64Cu-DOTA-AE105 [23], 
68Ga-DOTA/NODAGA-AE105 [24], and 
18F-AlF-NOTA-AE105. Initially, we obtained very 
promising results using 64Cu-DOTA-AE105, where a 
high tumor-to-background was found and a signifi-
cant correlation between tumor uptake values and 
levels of uPAR expression were noted, thus validating 
the in vivo specificity of this particular PET probe [19]. 
However, the use of DOTA as a general chelator for 
64Cu has been challenged in a number of studies, 
where its relatively low kinetic stability allegedly en-
ables a significant transchelation and/or transmetal-
lation of 64Cu in vivo to superoxide dismustase and 
metallothionien in liver as well as albumin in the 
blood circulation. This suboptimal chela-
tion-chemistry consequently causes an elevated 
non-specific uptake in these compartments [25, 26]. In 
line with these limitations, we also noted a relatively 
high uptake in both liver and blood in tumor bearing 
mice using 64Cu-DOTA in our studies [18, 19]. 
This inherent in vivo instability of the 
64Cu-DOTA complex has prompted an extensive 
search for improved radionuclide metal chelators 
with higher in vitro and in vivo stability [27]. 
First,  1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraa
cetic acid (TETA) demonstrated higher in vivo stability 
compared to DOTA, but its baseline 64Cu dissociation 
still resulted in binding to superoxide dismutase in 
vivo [28]. Second, introduction of several tetra-amine 
based macrobicyclic chelators, in which an ethylene 
bridge connects two nonadjacent nitrogens, signifi-
cantly improve their in vivo stability compared to the 
monocyclic DOTA and TETA [29-32]. In particular, 
the use of CB-TE2A as chelator for 64Cu has been used 
with success in a number of in vivo studies for PET 
imaging of integrins [33, 34], somatostatin receptor 
subtype 2 (SSTR2) [35, 36], epidermal growth factor 
receptor (EGFR) [37] and gastrin-releasing peptide 
receptor (GRPr) [38, 39], where superior tu-
mor-to-background ratios were reported in all cases 
compared to the DOTA counterparts. Recently, a 
CB-TE2A analogue with a propionamide functional-
ized linker (CB-TE2A-PA) was developed by Boswell 
et al. [40] (Figure 1). The virtue of this macrobicyclic 
chelator is that it engages all six coordination sites of 
Cu2+ thus forming an uncharged Cu complex in the 
final peptide conjugated PET probe, in contrast to the 
positively charged and five coordinated complex us-
ing the original CB-TE2A. 
The aims of the present study are to perform the 
first head-to-head in vitro and in vivo evaluation of the 
two cross-bridge cyclam chelators CB-TE2A and 
CB-TE2A-PA, conjugated to AE105 for uPAR PET 
imaging, and to compare the tumor-to-background 
ratios with the DOTA-conjugate analogue in vivo in 
mice carrying human U87MG glioblastoma xeno-
transplants. 
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Fig 1. Chemical structures of the uPAR targeting ligands: CB-TE2A-AE105, CB-TE2A-PA-AE105 and inactive control peptide CB-TE2A-PA-AE105mut, 
where Phe→Glu and Trp→Glu replacements grossly impairs the AE105-uPAR binding interface defined by the corresponding X-ray crystal structure [15]. 
 
Materials and methods 
Chemical reagents 
All commercial chemicals were of analytic grade 
and were purchased from Sigma-Aldrich, CheMatech, 
Fluka, Iris Biotech GmbH, or Rapp Polymere GmbH, 
and used without further purification unless other-
wise stated. NMR was performed using a Bruker 
Advance 300 spectrometer and matrix assisted laser 
desorption mass spectrometry (MALDI-MS) was 
performed on a Bruker autoflex II TOF/TOF (Bruker 
Daltonics, Germany). Analytical HPLC was per-
formed on a Dionex UltiMate 3000, using a Phenom-
enex Gemini 110 Å C18 column (3 µm, 4.6 × 50 mm) 
with a flow rate of 1.0 mL/min and a 10 minutes lin-
ear gradient going from 95% H2O/5% acetonitrile 
with 0.1% HCOOH to 100% acetonitrile 0.1% 
HCOOH. Preparative HPLC was performed on a Di-
onex UltiMate 3000, equipped with a Phenomenex 
Gemini-NX C18 110 Å column operated at a flow rate 
of 10.0 mL/min and a 30 minutes linear gradient from 
95% H2O/5% acetonitrile with 0.1% TFA to 100% ac-
etonitrile with 0.1% TFA. 2-(4,7,10-tris(2-tert-butoxy- 
2-oxoethyl)-1,4,7,10-tetraazacyclo-dodecan-1-yl)-aceti
c acid (DOTA-tris(tBu) ester) was purchased from 
CheMatech (Dijon, France). 64CuCl2 in 0.1 M HCl was 
obtained from Risø (DTU, Denmark). Recombinant 
human uPAR and pro-uPA were expressed in Dro-
sophila S2-cells and purified as described [41, 42].  
General methods for solid-phase peptide syn-
thesis  
Peptide synthesis was performed using Nα-Fmoc 
protected amino acids and HBTU/HOBt activation 
using a polystyrene resin with 2-Cl-Trityl linker (0.61 
mmol/g) or Tentagel resin with a trityl linker (0.20 
mmol/g). HBTU (3.7 equiv.) HOBt/HOAt (4:1, 4 
equiv.), Fmoc-AA-OH (4 equiv.), DIEA (7.2 equiv.) in 
N-methyl-2-pyrrolidone (NMP) were used. Preactiva-
tion (5 min) and couplings (90 min). Fmoc deprotec-
tion was performed by two incubations (15 min each) 
in piperidine/NMP (1:4). Following peptide assembly 
and coupling to the respective macrocyclic chelator, 
the resin was washed extensively with NMP and 
CH2Cl2, before the conjugates were released by 2 
hours incubation with TFA/H2O/triethylsilane 
(95:2.5:2.5). The released peptide was subsequently 
collected by filtration and pooled with the two washes 
with TFA used to clean the resin. This TFA-peptide 
mixture was stirred at room temperature for 24 hours 
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before TFA was removed under a stream of nitrogen 
and the peptide was precipitated with diethyl ether. 
The synthesized peptides were dissolved in a mini-
mum amount of H2O/acetonitrile (2:1) before being 
purified by preparative HPLC and lyophilized.  
Synthesis of cross-bridged macrobicyclic che-
lators  
Compound 2: 1,4,8,11-tetraazabicyclo[6.6.2] 
hexadecane (CB-Cyclam) [29, 43].  
 
 
In brief; a solution of 5.5 g 1,4,8,11- 
tetraazacyclotetradecane (27.5 mmol) [cyclam 1] in 
100 mL EtOH was added to 5.5 mL glyoxal (40 % in 
H2O) and the mixture was left stirring for 16 h. The 
mixture was evaporated and re-dissolved in 150 mL 
acetonitrile. To this solution was added 25 mL benzyl 
bromide and 300 mg tetrabutylammonium iodide (1.8 
mmol). The mixture was stirred for 40 h before the 
N,N’-dibenzylated product was precipitated from the 
reaction mixture and collected by filtration (10 g, 
90%). 
A fraction of this precipitate (2.1 g, 5.1 mmol) 
was dissolved in 50 mL EtOH, added 400 mg NaBH4 
(10.5 mmol), stirred at room temperature until the 
reaction was complete according to LCMS (1 h), and 
finally quenched by adding 5 mL NH4Cl (aq.), and left 
stirring overnight. After addition of 100 mL saturated 
NaHCO3 (aq.), the aqueous phase was extracted with 
3 x 100 mL CH2Cl2. The product was isolated by 
evaporation (2.1 g), dissolved in 20 mL AcOH and 5 % 
(w/w) Pd/C, degassed (Ar), connected to hydrogen 
balloon, and stirred overnight (16 h). The spent cata-
lyst was removed by filtration, the volatile solvent 
was evaporated, and the remaining solid redissolved 
in 20 mL H2O. The pH of the solution was adjusted to 
14 by solid NaOH, extracted with 6 x 25 mL benzene, 
and the organic phase was finally dried (NaSO4) and 
evaporated under reduced pressure to produce a clear 
yellow oil (550 mg, 47%). NMR was in accordance 
with previous published data [31].  
Compound 3: 5-(tert-butoxy)-4-(11-(2-(tert- 
butoxy)-2-oxoethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadec
an-4-yl)-5-oxopentanoic acid (protected CB-TE2A- 
PA). A solution of 800 mg CB-Cyclam (3.53 mmol) 
[compound 2] in 200 mL acetonitrile received 2 g 
K2CO3 and 1325 mg (3.71 mmol) α-bromoglutaric ac-
id-1-tert-butylester-5-benzyl ester (in 4 portions over 
24 h). 790 mg (4.05 mmol) tert-butyl bromoacetate was 
subsequently added to this suspension, left stirring at 
room temperature (4 h) before being acidified 
with AcOH and concentrated by evaporation. 
The benzyl group was removed by hydrogena-
tion (THF, Pd/C, 4 bar, 18 h), the catalyst re-
moved by filtration, and the mixture purified by 
HPLC yielding 1022 mg [compound 3] (55%). 
Compound 4: 4,11-bis(carboxymethyl)- 
1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2
A). To a solution of 500 mg CB-Cyclam (2.21 
mmol) [2] in 100 mL acetonitrile were added 1.5 
g K2CO3 and 900 mg (4.66 mmol) tert-butyl 
bromoacetate. The mixture was stirred 24 h at 
room temperature, acidified with AcOH, con-
centrated by evaporation, and finally purified 
by HPLC. Yield 382 mg, 38%. The tert-butyl 
groups were removed prior to use to generate [com-
pound 4] by treatment with TFA at room temperature 
for 6 hours (important for complete removal).  
Synthesis of uPAR-targeting peptides with 
N-terminal macrocyclic chelators 
The uPAR-targeting core peptide AE105 
(Asp-Cha-Phe-(D)Ser-(D)Arg-Tyr-Leu-Trp-Ser) and a 
corresponding inactive variant AE105mut 
(Asp-Cha-Glu-(D)Ser-(D)Arg-Tyr-Leu-Glu-Ser) were 
synthesized using Nα-Fmoc protected amino acids 
and a polystyrene resin with 2-Cl-Trityl linker (0.61 
mmol/g). These peptides (0.1 mmol) were conjugated 
in situ on the resin by adding either 137 mg tert-butyl 
protected CB-TE2A (0.40 mmol) or 211 mg 
CB-TE2A-PA (0.40 mmol), which were pre-activated 
with 137 mg N[(1H-benzotriazol-1-yl) 
(dimethylamino)methylene]-N-methylmethanamo-
nium hexafluorophosphate-N-oxide (0.36 mmol) and 
0.12 mL N,N-diisopropylethylamine (0.72 mmol) in 2 mL 
N-methyl-2-pyrrolidinone. The mixture was shaken 
for 2 hours, the peptide conjugates released with 
TFA/H2O/triethylsilane (95:2.5:2.5), and purified by 
preparative HPLC using a Phenomenex Gemini-NX 
C18 110 Å column running at a flow rate of 10 
mL/min and a 30 minutes linear gradient from 95% 
H2O/5% acetonitrile with 0.1% TFA to 100% acetoni-
trile with 0.1% TFA. Yields of the purified peptides 
were: CB-TE2A-AE105 (10 mg; MH+: 1550.74 Da/Δm 
NH
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0.09 Da), CB-TE2A-AE105mut (24 mg; MH+: 1547.81 
Da/Δm 0.08 Da ), CB-TE2A-PA-AE105 (16 mg; MH+: 
1622.91 Da/Δm 0.06 Da), CB-TE2A-PA-AE105mut (4 
mg; MH+: 1547.81 Da/Δm 0.04 Da). DOTA-AE105 was 
synthesized as previously described [19].  
Radiochemistry 
Radiolabeling of all uPAR-targeting peptides 
conjugated to various macrocylic chelators (DOTA, 
CB-TE2A and CB-TE2A-PA) (Figure 1) with 64Cu were 
done by adding 2 nmol conjugated peptide to a vial 
containing 500 µL sodium acetate buffer (0.5 M, pH 8) 
and 50 µL (approx. 100 MBq) 64CuCl2 in 0.1 M HCl. 
The solution was heated to 95°C for 30 min. After 
completion of the synthesis a small aliquot was re-
trieved for analysis using RP-HPLC as previously 
described [19]. The reaction mixture was then passed 
through a C18 SepPak cartridge and free Cu2+ was 
eluded with 5 mL water. The radiolabeled peptide 
was finally eluted with 0.5 mL ethanol and diluted in 
water to reduce the ethanol concentration below 5% 
before tail vein injection. The radiochemical purity of 
the final product was determined by RP-HPLC. This 
protocol typically yielded 95 MBq of radiolabeled 
peptide with a radiochemical purity of 95-97%. The 
amount of unlabeled Cu2+ was less than 1% in the 
final product. 
Potency and specificity of the targeting con-
structs 
To assess the penalty on the uPAR-binding af-
finity of AE105 by conjugation of CB-TE2A or 
CB-TE2A-PA to its α-amino-group, the inhibitory 
effect (IC50) of 3-fold dilution series the corresponding 
conjugates on the interaction between immobilized 
pro-uPA and 0.5 nM uPAR were assessed by surface 
plasmon resonance and compared to that of the un-
modified AE105. These studies were enabled by 
choosing running conditions that confer strict mass 
transport limitations on the binding reaction between 
pro-uPA and uPAR, as outlined previously in detail 
[44]. The direct binding between immobilized uPARwt 
(28 fmol/mm2) and 2-fold dilution series of the vari-
ous targeting constructs were also measured by sur-
face plasmon resonance using a Biacore T200 operated 
at 20°C and a flow rate of 50 µL/min running buffer 
(i.e. 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 
0.1 % (v/v) surfactant P-20 at pH 7.4). Regeneration of 
the CM5 sensor chip was accomplished by two con-
secutive 20 µL injections of 1 M formic acid. Kinetic 
rate constants (kon and koff) were derived by fitting the 
double referenced data to a 1:1 binding model using 
the evaluation software supplied with the instrument. 
Cell line and animal model 
U87MG glioblastoma cancer cells expressing 
high levels of uPAR expression [18, 19] were obtained 
from the American Type Culture Collection (Manas-
sas, VA, USA) and culture media was obtained from 
Invitrogen Co. (Carlsbad, CA, USA). The cell line was 
cultured in DMEM supplemented with 10% (v/v) 
fetal bovine serum and 1% (v/v) penicil-
lin/streptomycin at 37°C and 5% CO2. Xenografts of 
human U87MG glioblastoma cancer cells was estab-
lished by injection of 200 µl cells (1 x 108 cells/mL) 
suspended in 100 µL Matrigel (BD Biosciences, San 
Jose, CA, USA), subcutaneously into the left and right 
flank of female NMRI nude mice obtained from Ta-
conic, under anesthesia by Fentanyl (Hypnorm®) / 
Midazolam (Doricum®). All animal experiments were 
performed under a protocol approved by the Animal 
Research Committee of the Danish Ministry of Justice. 
MicroPET/CT Imaging 
Ten minutes static PET scans were acquired on a 
small animal PET Focus 120 scanner (Siemens Medical 
Solutions, Malvern, PA) 1 and 22 hrs post i.v. injection 
of approximately 10 MBq radiolabeled peptide. 
PET/CT scanning conditions were all set as described 
previously [19]. Results were analyzed using Inveon 
software (Siemens Medical Solutions) and PET data 
was expressed as percent of injected dose per gram 
tissue (%ID/g) based on manual region-of-interest 
drawing on fused PET-CT images for better anatom-
ical localization of organs/tissues of interest. 
Biodistribution studies 
Biodistribution studies were performed as de-
scribed [19]. In brief, Nude mice bearing U87MG 
xenografts received 2-3 MBq of radiolabeled peptide 
by tail-vein injections. All mice were euthanized after 
1 or 22 hrs post tracer injection. Blood, tumor and 
major organs were collected (wet-weight) and the 
radioactivity was measured using a γ-counter from 
Perkin Elmer, MA, USA (n=4 mice/group). 
uPAR ELISA 
Levels of uPAR in resected U87MG tumors ly-
sates were determined by a validated ELISA as de-
scribed [19] with one minor improvement. In the 
present study, we used a mechanical tissue homoge-
nization (Precellys, Bertin Technologies) to pulverize 
the resected and frozen tumor xenograft as compared 
to the manual homogenization used previously. All 
data measurements were performed in duplicates. 
Statistical analysis 
All quantitative data are expressed as means ± 
SEM (standard error of the mean) and means are 
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compared using one-way ANOVA. P values ≤ 0.05 
were considered statistically significant. 
Results 
Impact on uPAR-targeting affinity by chemical 
conjugation to various macrocyclic chelators 
In the present study, we synthesized and puri-
fied two new PET derivatives of a 9-mer linear pep-
tide AE105 [22], which targets human uPAR with high 
affinity and specificity in vivo, by conjugating it to 
different macrobicyclic chelators using its 
NH2-terminus (Figure 1). Our synthesis protocol 
yielded mg quantities of pure products. The impact 
on uPAR binding by conjugating AE105 to these 
macrocyclic chelators was subsequently tested by 
employing two different assay platforms based on 
surface plasmon resonance. In the first array of anal-
yses, we measured the inhibitory effect (IC50-values) 
of these peptides in solution on the binding of 0.5 nM 
uPAR to immobilized pro-uPA. Under such equilib-
rium binding conditions, we observed no significant 
differences in the inhibitory potencies of the various 
AE105 conjugates yielding IC50-values between 5.9 
and 6.7 nM (Figures 2A, 2B, and Table 1). No inhibi-
tion was observed for the corresponding control pep-
tides at the highest concentrations tested (600 nM). In 
the second array of analyses, we measured the direct 
binding of the conjugated peptides to immobilized 
uPAR on the sensor chip to obtain the kinetic rate 
constants for these interactions. In general, neither kon 
nor koff differs profoundly between the different 
AE105 derivatives giving rise to KD-values in the 
lower nanomolar range, which is in excellent agree-
ment with the recorded IC50-values (Table 1). Never-
theless, CB-TE2A-PA-AE105 did present a slightly 
weaker binding to immobilized uPAR (KD 27 nM) as 
compared to the other derivatives (KD 8-12 nM) indi-
cating that the more bulky propionamid linker in this 
conjugate may introduce a moderate imperfection of 
the uPAR•AE105 interface. Importantly, none of the 
control peptides revealed any specific interaction with 
immobilized uPAR in this direct binding assay. Rep-
resentative real-time binding profiles for these kinetic 
analyses are shown in Figures 2C and 2D for 
CB-TE2A-PA-AE105 and its corresponding 
non-binding CB-TE2A-PA-AE105mut.  
 
Fig 2. Binding properties of uPAR-targeting PET probes using surface plasmon resonance. The inhibitory profiles of CB-TE2A-AE105 and 
CB-TE2A-PA-AE105 and their corresponding inactive control peptides are shown in panels A and B, respectively. In these experiments the binding of 0.5 nM 
recombinant uPAR to immobilized pro-uPA (4300 RU ~ 93 fmol/mm2) are recorded under conditions conferring severe mass transport limitations. The 
amount of residual, unoccupied uPAR was calculated from the linear association rates in the initial phases of the binding reaction. The IC50-values were 
calculated by fitting the data to a four-parameter logistic model. The kinetics of the interaction between immobilized uPAR and a 2-fold dilution series of 
CB-TE2A-AE105 and its corresponding inactive control is shown in panels C and D, respectively. Highest concentration of the peptide tested is 100 nM and 
25 nM is measured twice to validate reproducibility. Repeat measurements are shown in blue and buffer runs in green. 
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Table 1. Binding properties of selected uPAR targeting pep-
tide-based PET probesa 
Ligand kon                  
(106 M-1s-1) 
koff              
(10-3 s-1) 
KD 
(10-9M) 
IC50 
(10-9M) 
AE105 0.62 ± 0.34 7.6 ± 0.7 12 6.7 ± 1.6 
     
DOTA-AE105 0.46 ± 0.19 4.3 ± 0.6 9.4 6.7 ± 1.0 
DOTA-AE105mut nbb nbb nbb >> 103 
     
CB-TE2A-AE105 0.60 ± 0.30 4.6 ± 0.1 7.7 5.9 ± 1.0 
CB-TE2A-AE105mut nbb nbb nbb >> 103 
     
CB-TE2A-PA-AE105 0.40 ± 0.13 10.8 ± 0.1 27 6.1 ± 1.0 
CB-TE2A-PA-AE105mut nbb nbb nbb >> 103 
aThe IC50-values for competing the binding between 0.5 nM uPARwt and immobi-
lized pro-uPA were determined as outlined in Figures 2A and 2B. Kinetic rate 
constants (kon and koff) for the direct interaction with immobilized uPARwt were 
determined by surface plasmon resonance using a Biacore T200 as illustrated for 
CB-TE2A-PA-AE105 and its inactive version in Figure 2C and 2D. The equilibrium 
dissociation constant (KD) was calculated as koff/kon. bnb: no measurable binding up 
to 200 nM peptide. 
 
 
 
In vitro stability of Cu-complexes of the various 
uPAR-targeting peptides 
Our three purified, active uPAR-targeting pep-
tides DOTA-AE105, CB-TE2A-AE105 and 
CB-TE2A-PA-AE105 were subsequently loaded with 
the natural occurring isotopes of Cu(II) (69.2 % 63Cu 
and 30.8 % 65Cu) by incubating them with 10 mM 
CuCl2 for 60 minutes at 70°C and the complexes were 
subsequently purified by RP-HPLC (data not shown). 
The pure complex preparations were analyzed by 
MALDI-MS after co-crystallization with 
α-cyano-4-hydroxycinnamic acid (ACHA) or sin-
napinic acid (SA) using identical laser pulse energies 
and delayed extraction times (130 ns) for recording 
the MS spectra (shown in Figure 3). Despite our pure 
peptide-complex preparations are stable as judged 
after repeat RP-HPLC chromatography, the 
MALDI-MS spectra recorded in ACHA, nevertheless, 
clearly reveals the occurrence of a variable amount of 
demetallated peptide with the following ranking ac-
cording to stability: CB-TE2A-PA-AE105 (19 %) > 
CB-TE2A-AE105 (36 %) >> DOTA-AE105 (57 %), 
where the observed loss of Cu induced by laser de-
sorption from ACHA are shown in brackets (Figure 
3B to 3D and Table 2). The difference between the 
monoisotopic masses of the demetallated species and 
the corresponding Cu-complexes is 60.9 Da in both 
matrices for all three constructs corresponding to the 
mass of 63Cu2+ minus two protons. The isotope enve-
lopes recorded for the three Cu-complexes are, none-
theless, very different and simulations of the isotope 
distributions (Figure 3, left) estimate the abundances 
of complexed Cu(II) to be markedly diminished for 
63Cu-DOTA-AE105 (17 %) compared to both 
63Cu-CB-TE2A-AE105 (65 %) and 63Cu-CB-TE2A- 
PA-AE105 (75 %). The molecular basis for this insta-
bility of the complexes during the matrix-assisted 
desorption process is presumably an in-source decay, 
where gas phase collisions in the electron dense 
MALDI plume during delayed extraction cause a re-
duction of Cu(II) to Cu(I) by electron transfer [45-47]. 
The reduction of complexed Cu(II) to Cu(I) by gas 
phase electron transfer during the MALDI process 
depends on the recombination energy of Cu(II), which 
is correlated to the thermodynamic probability of 
electron uptake. Particularly relevant to our present 
study is the observation, that high affinity binding to 
Cu(II) lowers its recombination energy, which ac-
cordingly renders Cu(II) tethered to strong chelating 
groups less prone to electron uptake [47]. Our ex-
perimental data in Fig. 3 clearly show, that reduction 
of Cu(II) to Cu(I) occurs much more readily when 
bound to DOTA as compared to the two macrobicy-
clic chelators and we ascribe this higher reactivity to a 
higher recombination energy, which in turn reflects 
an attenuated gas-phase binding affinity. In this re-
spect, it should be emphasized that the binding en-
ergy of Cu(II) generally is much higher compared to 
Cu(I), which is illustrated by the differences in the 
total binding energies between Cu(I) and Cu (II) to 
three imidazoles in the gas phase (625 kJ/mol and 
2000 kJ/mol, respectively [47]). In summary, we en-
vision that reduction of Cu(II) to Cu(I) in the MALDI 
process substantially weakens the interaction between 
the copper ion and the macrocyclic chelator and this 
drives the loss of copper (demetallation) via the 
Cu(I)-peptide complexes during the internal energy 
build-up in the MALDI plume. Sinapinic acid is a 
“softer” matrix yielding ions with lower internal en-
ergy and the extent of demetallation of Cu(I)-peptide 
complexes is thus lower for this matrix. From these 
experiments it is evident that both our cross-bridged 
macrobicyclic chelators are by far more resilient to-
wards reduction mediated demetallation than DOTA, 
with CB-TE2A-PA-AE105 showing the best perfor-
mance (Figure 3 and Table 2).  
 64Cu radiolabeling of ligands 
The radiochemical yield obtained for all three 
uPAR-targeting ligands were >95% using 2 nmol 
peptid-conjugate and 30 min total reaction time (95oC, 
pH 8). Using lower amounts of peptide-conjugate 
significantly reduced the overall yields, with less than 
10% yield using 0.5 nmol CB-TE2A-AE105 (Figure 4). 
The radiolabeled peptides were purified on a Sep-Pak 
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C18 cartridge to remove unbound 64Cu, which re-
sulted in > 95% pure products. The specific activities 
of the final radiolabeled conjugates were all approx-
imately 50 GBq/µmol.  
Table 2. Laser-induced in-source reduction of Cu(II) complexed to various macrocyclic chelators.  
Ligand - matrix1 Demetallation (%)2 63Cu(II)/ 63Cu (%)3 Isotope control (%)4 
DOTA-AE105    
CHCA 57.1 ± 8.0 15.3 ± 5.2 50.9 ± 0.4 
SA 18.1 ± 6.9 41.1 ± 4.9 51.1 ± 1.2 
CB-TE2A-AE105    
CHCA 36.2 ± 7.8 44.8 ± 3.1 52.2 ± 1.6 
SA 23.2 ± 3.3 46.0 ± 2.1 51.3 ± 0.9 
CB-TE2A-PA-AE105    
CHCA 19.2 ± 2.9 45.6 ± 1.4 51.0 ± 0.9 
SA 4.4 ± 1.2 46.6 ± 1.5 50.0 ± 3.5 
1The following MALDI matrices were used in this study α-cyano-4-hydroxycinnamic acid (CHCA) and sinapinic acid (SA). 2Estimation of the degree of in-source prompt 
dissociation of Cu from the macrocyclic chelators. The relative areas of the isotope envelopes representing the demetallated peptide (M) and the Cu-complexed peptide 
(M+Cu) were calculated for each matrix: [M/M+(M+Cu)]x100. The data are shown for 8 independent sample depositions in CHCA and SA. 3Surrogate marker for the degree 
of laser-induced Cu(II) to Cu(I) reduction that still persists in the Cu-complexes leaving the source of the mass spectrometer. The relative peak heights corresponding to 
63Cu(II)/63Cu were calculated for both matrices (n=8) as [b/(b+(b+1)]x100 in Figure 3. 4Quality control for the above surrogate marker assessment of Cu(II) reduction. The 
relative peak heights corresponding to the demetallated peptides were measure for both matrices in the same MALDI spectra as [a/(a+(a+1)]x100 in Figure 3 (n=8).  
 
 
Fig 3. Chemical stability of different macrocyclic Cu-complexes probed by MALDI-MS. MALDI-MS spectra are recorded under identical 
conditions for Cu-DOTA-AE105 in SA (panel A) and ACHA (panel B), Cu-CB-TE2A-AE105 in ACHA (panel C), and for Cu-CB-TE2A-PA-AE105 in ACHA 
(panel D). To the left of each panel is shown the best fit obtained for the isotope envelopes using the oxidation state of the bound Cu as the only floating 
parameter (Cu(II) or Cu(I)). The lower case letters in the MALDI-MS spectra indicates the monoisotopic peaks of the following singly charged molecular 
species: a) corresponds to the demetallated peptide, [M + H]+; b) corresponds to the Cu-chelated peptide with 63Cu(II), [M – H + 63Cu(II)]+. 
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Fig 4. Radiolabeling uPAR targeting peptides. Radiochemical yields for 
64Cu labeling using different amounts of CB-TE2A-AE105 and 
CB-TE2A-PA-AE105 incubated 30 min at 95°C and pH 8.0. Above 2 nmol 
conjugated peptide, no significantly difference in labeling yield were ob-
served, whereas CB-TE2A-PA-AE105 gave a higher yield below 2 nmols. 
Head-to-head in vivo PET comparison 
In the first experiment, a head-to-head in vivo 
PET imaging study of 64Cu-DOTA-AE105, 
64Cu-CB-TE2A-AE105 and 64Cu-CB-TE2A-PA-AE105 
for uPAR PET imaging was performed in parallel on a 
cohort of nude mice inoculated at the same time with 
human U87MG tumor cells. Such xenografts generally 
express high levels of uPAR [19]. All three ligands 
showed a high tumor uptake, with 
64Cu-CB-TE2A-AE105, 64Cu-CB-TE2A-PA-AE105, and 
64Cu-DOTA-AE105 having uptake values of 3.5±0.8 
%ID/g, 4.2±0.6 %ID/g and 4.8±0.7 %ID/g, respec-
tively (Figure 5A) providing a good contrast for im-
aging tumor localization by PET scanning already 
after 1h p.i. (Figure 5E). After 22 hrs the relative tumor 
uptake values declined as expected for the two mac-
robicyclic derivatives to 2.0±0.3 %ID/g and 1.6±0.3 
%ID/g, whereas the DOTA-based probe remained 
unaltered at 4.5±2.2 %ID/g. 
 
Fig 5. Quantitative ROI analysis from PET 
imaging of all three uPAR ligands. Tumor 
uptake values (%ID/g) after 1 hr and 22 hrs are 
shown in panel A, tumor-to-blood ratio in panel 
B, liver uptake values in panel C, and tu-
mor-to-liver ratio in panel D. Representative 
transverse images of 64Cu-DOTA-AE105 and 
64Cu-CB-TE2A-AE105, 64Cu-CB-TE2A-AE105 
are shown in the lower panel for 1 h p.i.. White 
arrow indicates tumor. ** p<0.01, *** p<0.001. 
(n=8 tumors). 
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As reported previously by others [26, 34, 38], we 
also observed a significant difference in the hepatic 
uptake value for 64Cu-CB-TE2A-AE105 as compared 
to 64Cu-DOTA-AE105 at 22hrs (p<0.001). This reduced 
hepatic uptake was, however, even more pronounced 
for 64Cu-CB-TE2A-PA-AE105 (Figure 5C) indicating 
that this particular PET tracer exhibits the better in 
vivo stability of the three tested uPAR ligands. Unex-
pectedly, no significant differences in tumor-to-liver 
ratios were found in this study between 
64Cu-DOTA-AE105 and 64Cu-CB-TE2A-AE105 after 
either 1h (0.39±0.10 and 0.37±0.06) or 22hrs (0.58±0.06 
and 0.61±0.09), respectively (Figure 5D). In contrast, a 
significantly improved tumor-to-liver ratio was im-
portantly found for 64Cu-CB-TE2A-PA-AE105 (1h: 
0.99±010, p<0.001 and 22hrs: 1.18±0.27, p<0.001) 
compared to both 64Cu-DOTA-AE105 and 
64Cu-CB-TE2A-AE105. 64Cu-DOTA-AE105 presents a 
significantly higher tumor-to-blood ratio (3.66±1.09, 
p<0.01) compared to 64Cu-CB-TE2A-AE105 
(2.55±0.25) and 64Cu-CB-TE2A-PA-AE105 (2.46±0.59) 
1h p.i. (Figure 5B), but this difference is not retained in 
images recorded after 22 hrs.  
Biodistribution 
Biodistribution studies were performed in nude 
mice bearing uPAR-positive U87MG xenografts. 
64Cu-CB-TE2A-AE105 and 64Cu-CB-TE2A-PA-AE105 
were administered by a single i.v. injection and organs 
and tissue were collected after 1h and 22 hrs p.i. Fig-
ures 6A and 6B show the radionuclide uptake after 1 h 
and 22 hrs, respectively. Both ligands cleared rapidly 
from the blood (<2.0 %ID/g after 1 h). Kidney uptake 
decreased more slowly, with approximate 14 %ID/g 
after 1 h and 5% ID/g at 22 hrs p.i. Overall, a very 
similar general uptake was observed for each of the 
ligands, although 64Cu-CB-TE2A-PA-AE105 has a 
tendency to clear faster from non-target tissues.  
A 2-fold increase in hepatic uptake was consist-
ently observed after 1 h and 22 hrs for 
64Cu-CB-TE2A-AE105 (1 h: 11.2±1.2 %ID/g, 22 hrs: 
3.6±0.4 %ID/g) compared to 
64Cu-CB-TE2A-PA-AE105 (1 h: 4.8±0.2 %ID/g, 22 hrs: 
1.6±0.1 %ID/g). Importantly, this property improves 
the tumor-to-liver ratio significantly for 
64Cu-CB-TE2A-PA-AE105 (1 h: p<0.01 and 22 hrs: 
p<0.001, Figure 6C), which is excellently aligned with 
the previous PET scanning profiles recorded for a 
similar experiment (Fig. 5E) thus validating the im-
proved in vivo partitioning of this particular 
uPAR-targeting PET tracer. All data from the biodis-
tribution study are shown in Table 3. 
 
 
 
 
 
 
Fig 6. Biodistribution profiles of uPAR PET tracers. Results for 
64Cu-CB-TE2A-AE105 and 64Cu-CB-TE2A-PA-AE105 are shown after 1 h 
(panel A) and 22 hrs (panel B). A significantly higher tumor-to-liver ratio was 
found for 64Cu-CB-TE2A-PA-AE105 after both 1h (p>0.01) and 22 h 
(p>0.001) (panel C). (n=4 mice/group). 
 
 
 
 
 
 
 
 Theranostics 2013, Vol. 3, Issue 9 
 
http://www.thno.org 
628 
Table 3. Biodistributions of new cross-bridged uPAR PET trac-
ersa .  
 64Cu-CB-TE2A-AE105 64Cu-CB-TE2A-PA-AE105 
Organ 1 h  
(%ID/g) 
22 hrs 
(%ID/g) 
1 h  
(%ID/g) 
22 hrs 
(%ID/g) 
Blood 1.4 ± 0.2 0.4 ± 0.1 2.0 ± 0.3 0.2 ± 0.1 
Liver 11.2 ± 1.2 3.6 ± 0.4 4.8 ± 0.7 1.6 ± 0.1 
Kidney 15.0 ± 1.0 5.2 ± 1.4 14.0 ± 1.6 4.8 ± 0.7 
Lung 5.5 ± 1.4 2.9 ± 0.4 4.3 ± 0.7 2.0 ± 0.8 
Spleen 6.2 ± 1.2 2.9 ± 0.7 2.8 ± 0.3 2.7 ± 0.3 
Heart 1.2 ± 0.1 1.0 ± 0.2 1.1 ± 0.1 0.6 ± 0.1 
Stomach 1.7 ± 0.6 1.1 ± 0.4 1.3 ± 0.8 0.7 ± 0.1 
Intestine 4.3 ± 1.1 2.1 ± 0.4 3.7 ± 0.8 1.3 ± 0.1 
Muscle 0.3 ± 0.1 0.2 ± 0.1 0.5 ± 0.2 0.1 ± 0.1 
Bone 1.1 ± 0.4 0.8 ± 0.3 0.9 ± 0.1 0.9 ± 0.3 
Brain 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
Tumor 3.6 ± 1.0 2.1 ± 0.3 3.0 ± 0.9 2.0 ± 0.3 
Tumor-to-nontumor 
ratios 
    
Tumor-to-blood 2.6 ± 0.5 5.2 ± 0.5 1.5 ± 0.4 9.3 ± 1.7 
Tumor-to-liver 0.3 ± 0.1 0.6 ± 0.1 0.7 ± 0.3 1.3 ± 0.2 
Tumor-to-kidney 0.2 ± 0.1 0.4 ± 0.1 0.2 ± 0.1 0.5 ± 0.1 
Tumor-to-intestine 0.8 ± 0.1 1.0 ± 0.2 0.9 ± 0.3 1.6 ± 0.2 
Tumor-to-muscle 1.4 ± 0.2 17.5 ± 8.0 7.5 ± 5.0 22.2 ± 15.3 
aThe biodistributions profiles and tumor to non-tumor ratios for 
64Cu-CB-TE2A-AE105 and 64Cu-CB-TE2A-PA-AE105 were established in nude mice 
bearing U87MG xenografts by gamma counting of resected organs. 
 
In vivo specificity study 
To demonstrate that the tumor uptake of the best 
performing PET-tracer (i.e. 64Cu-CB-TE2A-PA-AE105) 
is indeed caused by a specific targeting of uPAR ra-
ther than passive accumulation of free 64Cu2+, we 
measured the in vivo uptake by PET scanning of a 
non-binding version of our targeting probe labeled 
with 64Cu to the same specific activity. The successful 
abrogation of the targeting affinity of the designed 
control peptide towards uPAR was confirmed by 
surface plasmon resonance studies revealing the IC50 
to be reduced from 5-10 nM to >> 1µM for the dys-
functional peptide and no direct binding can accord-
ingly be measured (Figure 2 and Table 1). When par-
allel PET/CT images of this control PET probe were 
reconstructed for 1 h and compared to the corre-
sponding active uPAR-targeting probe, a significantly 
reduced tumor uptake was found (p<0.001, Figure 
7B). This effect is clearly visualized by the recon-
structed PET images (Figure 7A). The tumor uptake 
value was 5.4±0.7 %ID/g for 64Cu-CB-TE2A- 
PA-AE105 after 1 h. In contrast, the tumor uptake 
value in mice injected in parallel with the non-binding 
version 64Cu-CB-TE2A-PA-AE105mut having the same 
specific radioactivity was only 2.2±0.4 %ID/g after 1 
h. Importantly, the hepatic uptake values of these 
active and inactive PET-tracers were comparable after 
1 h (Figure 7B). Noteworthy, the hepatic uptake val-
ues (representing a non-target organ) were signifi-
cantly lower for the 64Cu-CB-TE2A-PA-AE105 
PET-tracer compared to both 64Cu-DOTA-AE105 and 
64Cu-CB-TE2A-AE105 (Figure 5C). Moreover, the dif-
ference in tumor uptake was clearly not related to 
differences in uPAR expression between the two 
groups as ELISA measurements on resected tumors 
lysates revealed comparable uPAR levels (Figure 7C). 
Combined these data unambiguously confirms the 
uPAR-targeting specificity of 64Cu-CB-TE2A- 
PA-AE105. 
Discussion 
Our present study reports on the synthesis and 
characterization of two new 64Cu labeled 
cross-bridged peptide antagonists that specifically 
targets human uPAR. Importantly, our data reveal 
that the new 64Cu-CB-TE2A-PA-AE105 PET-tracer in 
our experiments exhibits a much improved tu-
mor-to-liver ratio compared to both 
64Cu-CB-TE2A-AE105 and 64Cu-DOTA-AE105, which 
is in accordance with the in vitro stabilities we meas-
ured by MALDI-MS. 
The rational design of these uPAR-targeting 
PET-tracers was originally guided by our detailed 
knowledge on the structure-functional relationships 
that drive the biochemistry of this receptor - as re-
viewed recently [48]. Accordingly, we observed no 
significant impact on the affinity and specificity of the 
uPAR-targeting core-peptide by conjugation to any of 
the macrocyclic chelators employed in this study. 
Nonetheless, in the direct binding assay 
CB-TE2A-PA-AE105 did present a slightly weaker 
affinity to immobilized uPAR (KD 27 nM) as com-
pared to the other derivatives (KD 8-12 nM) indicating 
that the propionamid linker in this particular conju-
gate may introduce a moderate imperfection of the 
uPAR•AE105 binding interface. Despite this notion, 
we did not observe a similar difference in the 
IC50-values for the solution phase competition ex-
periments (Table 1) emphasizing the similar potencies 
of the various peptide conjugates. The differences 
observed in the direct binding to the immobilized 
receptor could therefore pertain to changes in the 
conformation of the inherently flexible uPAR [49] 
introduced by the immobilization chemistry, which is 
sensed only by the more bulky peptide conjugate i.e. 
CB-TE2A-PA-AE105. Importantly, none of the control 
peptides revealed any specific interaction with im-
mobilized uPAR in this direct binding assay further 
substantiating their usefulness as reporters of 
non-specific probe accumulation in vivo. 
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Fig 7. Specificity of uPAR imaging by 64Cu-CB-TE2A-PA-AE105 targeting. Representative sagittal PET/CT images for 64Cu-CB-TE2A-PA-AE105 and 
its corresponding inactive control peptide 64Cu-CB-TE2A-PA-AE105mut are shown after 1h (panel A). White arrows indicate location of the tumors. The 
corresponding quantitative ROI analysis of tumor and liver are shown (panel B). Levels of uPAR expression determined by ELISA in resected tumor lysates 
from mice sacrificed after termination of each imaging experiment are shown in (panel C). (n = 6 tumors (3 mice in each group). *** p<0.001. 
 
Radionuclide labeling of these uPAR targeting 
ligands with 64Cu2+ was completed within 30 min at 
95°C, pH 8 (yields > 95 %) using as little as 2 nmol 
conjugated peptide (Figure 4). This reaction kinetic is 
somewhat faster than those generally reported, where 
1 h to 2 hrs of incubation is typically required for 
completion [40, 50]. However, the relatively harsh 
radiolabeling conditions still limits radiolabeling to 
relatively stable peptide conjugates excluding radio-
labeling of proteins and antibodies. To overcome 
these limitations, a second-generation cross-bridge 
chelators incorporating methanephosphoric acid 
pendent arms (CB-TE2P and CB-TE1A1P) was re-
cently published [51, 52]. These chelators enable cop-
per radiolabeling at room temperature within 1 h and 
data shows improved biodistribution compared with 
CB-TE2A [53]. However, no conjugation to any pro-
teins using these chelators has yet been reported.  
The introduction of a propionamide arm in 
CB-TE2A-PA neutralizes the charge of the resultant 
copper complex in contrast to the original CB-TE2A 
chelator [31, 40], where one of the pendant carbox-
ylates is used for conjugation to the peptide. In our 
present study, we find that this modification does not 
affect the tumor uptake value, which is comparable to 
that of the CB-TE2A derivative, but importantly we 
observe a significantly reduced uptake of the 
CB-TE2A-PA derivative in non-target organs such as 
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the liver (p<0.001). Since hepatic accumulation of 
copper is a valid surrogate marker for compromised 
in vivo stability [26, 53] we propose that 
CB-TE2A-PA-AE105 possess a superior in vivo stabil-
ity compared to CB-TE2A-AE105. Both our new 
macrobicyclic PET-tracers targeting uPAR do, never-
theless, exhibit a higher stability than 
64Cu-DOTA-AE105 (Figure 5C). In line with this 
proposition is our new in vitro stability data based on 
MALDI in-plume reduction (Figure 3, Table 2) and a 
previous report, which states that positively charged 
64Cu-labeled cyclam and Et-cyclam chelates generally 
exhibit a higher liver accumulation compared to the 
corresponding neutral complex, 64Cu-labeled 3,9-DOC 
in rats [25]. 
Somewhat surprisingly, we found no significant 
differences in the tumor-to-liver ratios between 
64Cu-CB-TE2A-AE105 and 64Cu-DOTA-AE105 (figure 
5D), despite a significant reduction in the hepatic up-
take of 64Cu-CB-TE2A-AE105 at 22 hrs (Figure 5C). 
The well-established lower kinetic stability of the 
copper-DOTA complex in vivo [25, 26] may, however, 
represent a major confounding factor in such experi-
ments. The possible contribution from un-bound 64Cu 
during PET imaging is illustrated by high and persis-
tent tracer accumulations in e.g. U87MG xenotrans-
plants after tail vein injection of free 64Cu2+; 3.5±0.4 
%ID/g and 3.8±0.4 %ID/g at 1 h and 22 hrs, respec-
tively [54]. Accordingly, we speculate that the com-
monly observed high tumor uptake of 
64Cu-DOTA-conjugated ligands in particular, that we 
and others [51, 52] observe in mice 22 hrs after tracer 
administration, represents a composite signal from 
specific receptor targeting as well as non-specific ac-
cumulation of free 64Cu in the tumor tissue. A direct 
comparison of tumor uptake values in mice between 
64Cu-labeled DOTA conjugates and new metal che-
lating systems such as the cross-bridged conjugates 
used in this study should therefore be interpreted 
with some precaution due to the different magnitude 
of confounding effects inherent to tracer leakage in 
vivo from the employed macrocyclic chelators.  
At present only very few publications address 
the in vivo use of CB-TE2A-PA. In one study Liu et al 
[43] synthesize CB-TE2A-PA conjugated to cRGDyK 
(i.e. 64Cu-CB-TE2A-PA-c(RGDyK)) and used this 
PET-probe for imaging of αvβ3 integrin expression in 
PC3 prostate cancer xenografts in vivo, but a parallel 
comparison to the corresponding CB-TE2A conjugate 
was regrettably not attempted [43]. Nonetheless, by 
comparing the reported liver uptake data in mice 
from Liu et al. [43], (1 h: 1.4±0.1 %ID/g) with the liver 
uptake data of 64Cu-CB-TE2A-c(RGDyK) published 
by Anderson et al [55], (1 h: 3.9±2.0 %ID/g) a signifi-
cantly reduced liver uptake (2.8 fold, p<0.05) was in-
deed seen between the two chelators. Although this 
may be considered circumstantial evidence, it is in-
triguing that we find a similar difference in the he-
patic uptake in our controlled pairwise comparison of 
these chelators using a different receptor targeting 
ligand (2.2 fold, p<0.001).  
In conclusion, the present study selects 
64Cu-CB-TE2A-PA-AE105 as the most promising pep-
tide tracer for the specific detection of human uPAR 
expression in xenotransplanted mouse model systems 
by non-invasive PET imaging among those 64Cu- and 
68Ga-labeled derivatives of AE105 that we have tested 
[18-20]. It should, nevertheless, be emphasized that 
the confounding effects from the reduced stability of 
Cu-DOTA complexes that generally affects preclinical 
imaging in mouse model systems, do not necessarily 
translate directly to the clinical situation. Accordingly, 
the use of 64Cu-DOTA-TATE for PET imaging of so-
matostatin receptor expression in neuroendocrine 
cancer patients provides very high quality images 
with a high tumor-to-background contrast and low 
non-specific hepatic uptake [56]. Selection of the op-
timal PET tracer for future clinical imaging of uPAR 
expression in patients is therefore a composite process 
involving multiple factors and considerations. 
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